Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval von Prasad, Vinay, Mailankody, Sham

Volltext

Emerging immunotherapies in multiple myeloma von Shah, Urvi A, Mailankody, Sham

Volltext

T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma von Mailankody, Sham, Landgren, Ola

Volltext

The high price of anticancer drugs: origins, implications, barriers, solutions von Prasad, Vinay, De Jesús, Kevin, Mailankody, Sham

Volltext

Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells von Mi, Xiaoli, Penson, Alex, Abdel-Wahab, Omar, Mailankody, Sham

Volltext

Low-value approvals and high prices might incentivize ineffective drug development von Prasad, Vinay, McCabe, Christopher, Mailankody, Sham

Volltext

Comparative Effectiveness Questions in Oncology von Mailankody, Sham, Prasad, Vinay

Volltext

GPRC5D-Targeted CAR T Cells for Myeloma von Mailankody, Sham, Devlin, Sean M., Landa, Jonathan, Nath, Karthik, Diamonte, Claudia, Carstens, Elizabeth J., Russo, Douglas, Auclair, Romany, Fitzgerald, Lisa, Cadzin, Briana, Wang, Xiuyan, Sikder, Devanjan, Senechal, Brigitte, Bermudez, Vladimir P., Purdon, Terence J., Hosszu, Kinga, McAvoy, Devin P., Farzana, Tasmin, Mead, Elena, Wilcox, Jessica A., Santomasso, Bianca D., Shah, Gunjan L., Shah, Urvi A., Korde, Neha, Lesokhin, Alexander, Tan, Carlyn R., Hultcrantz, Malin, Hassoun, Hani, Roshal, Mikhail, Sen, Filiz, Dogan, Ahmet, Landgren, Ola, Giralt, Sergio A., Park, Jae H., Usmani, Saad Z., Rivière, Isabelle, Brentjens, Renier J., Smith, Eric L.

Volltext

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, de... von Piedra, Katrina, Peterson, Tim, Tan, Carlyn, Orozco, Jennifer, Hultcrantz, Malin, Hassoun, Hani, Mailankody, Sham, Lesokhin, Alexander, Shah, Urvi, Lu, Sydney, Patel, Dhwani, Derkach, Andriy, Wilkins, Cy R., Korde, Neha

Volltext

Granulocyte‐colony stimulating factor in COVID‐19: Is it stimulating more than just the bone marrow? von Nawar, Tamara, Morjaria, Sejal, Kaltsas, Anna, Patel, Dhruvkumar, Perez‐Johnston, Rocio, Daniyan, Anthony F., Mailankody, Sham, Parameswaran, Rekha

Volltext

Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospecti... von Wagner, Jeffrey, Marquart, John, Ruby, Julia, Lammers, Austin, Mailankody, Sham, Kaestner, Victoria, Prasad, Vinay

Volltext

Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies von Stuver, Robert, Shah, Gunjan L., Korde, Neha S., Roeker, Lindsey E., Mato, Anthony R., Batlevi, Connie L., Chung, David J., Doddi, Sital, Falchi, Lorenzo, Gyurkocza, Boglarka, Hamilton, Audrey, Lin, Ya-Hui, Jakubowski, Ann A., Joffe, Erel, Landau, Heather L., Lin, Richard J., Mailankody, Sham, Palomba, M. Lia, Park, Jae H., Perales, Miguel-Angel, Ponce, Doris M., Ramanathan, Lakshmi V., Salles, Gilles A., Scordo, Michael, Seo, Susan K., Shah, Urvi A., Stein, Eytan M., Straus, David, Usmani, Saad Z., Young, James W., Zelenetz, Andrew D., Noy, Ariela, Vardhana, Santosha A.

Volltext

Addendum: Low-value approvals and high prices might incentivize ineffective drug development von Prasad, Vinay, McCabe, Christopher, Mailankody, Sham

Volltext

Comparison of MALDI‐TOF mass spectrometry analysis of peripheral blood and bone marrow‐based flow cytometry for tracking measurable residual disease in patients with multiple myelo... von Eveillard, Marion, Rustad, Even, Roshal, Mikhail, Zhang, Yanming, Ciardiello, Amanda, Korde, Neha, Hultcrantz, Malin, Lu, Sydney, Shah, Urvi, Hassoun, Hani, Smith, Eric, Lesokhin, Alexander, Mailankody, Sham, Landgren, Ola, Thoren, Katie

Volltext

Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS) von Mailankody, Sham, Pfeiffer, Ruth M., Kristinsson, Sigurdur Y., Korde, Neha, Bjorkholm, Magnus, Goldin, Lynn R., Turesson, Ingemar, Landgren, Ola

Volltext

Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma von Hamadeh, Issam S, Friend, Reed, Mailankody, Sham, Atrash, Shebli

Volltext

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients von Kazandjian, Dickran, Hill, Elizabeth, Hultcrantz, Malin, Rustad, Evan H., Yellapantula, Venkata, Akhlaghi, Theresia, Korde, Neha, Mailankody, Sham, Dew, Alex, Papaemmanuil, Elli, Maric, Irina, Kwok, Mary, Landgren, Ola

Volltext

Second malignancies after multiple myeloma: from 1960s to 2010s von Thomas, Anish, Mailankody, Sham, Korde, Neha, Kristinsson, Sigurdur Y., Turesson, Ingemar, Landgren, Ola

Volltext

Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries von Green, Angela K, Curry, Michael, Trivedi, Niti, Bach, Peter B, Mailankody, Sham

Volltext

Accelerated single cell seeding in relapsed multiple myeloma von Landau, Heather J., Yellapantula, Venkata, Diamond, Benjamin T., Rustad, Even H., Maclachlan, Kylee H., Gundem, Gunes, Medina-Martinez, Juan, Ossa, Juan Arango, Levine, Max F., Zhou, Yangyu, Kappagantula, Rajya, Baez, Priscilla, Attiyeh, Marc, Makohon-Moore, Alvin, Zhang, Lance, Boyle, Eileen M., Ashby, Cody, Blaney, Patrick, Patel, Minal, Zhang, Yanming, Dogan, Ahmet, Chung, David J., Giralt, Sergio, Lahoud, Oscar B., Peled, Jonathan U., Scordo, Michael, Shah, Gunjan, Hassoun, Hani, Korde, Neha S., Lesokhin, Alexander M., Lu, Sydney, Mailankody, Sham, Shah, Urvi, Smith, Eric, Hultcrantz, Malin L., Ulaner, Gary A., van Rhee, Frits, Morgan, Gareth J., Landgren, Ola, Papaemmanuil, Elli, Iacobuzio-Donahue, Christine, Maura, Francesco

Volltext